heart ecg Topline results were announced from the phase 3 NODE-301 trial of etripamil nasal spray (Milestone Pharmaceuticals), a novel short-acting calcium channel blocker, being investigated for the ...

The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced.

(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...

Cardamyst is now FDA approved as a self-administered intranasal treatment for acute episodes of paroxysmal supraventricular tachycardia.

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

CHICAGO, IL — A nasal spray containing the calcium-channel blocker etripamil could allow patients to convert acute paroxysmal supraventricular tachycardia (PSVT) outside the hospital, phase 2 data ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, ...

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...